LUND, SE / ACCESS Newswire / April 29, 2026 / BioInvent International (STO:BINV)
"During the first quarter of 2026, our strategy remained centered on efficient resource allocation across our most advanced assets, BI-1808 (anti-TNFR2) and BI-1206 (anti-Fc?RIIB), with the goal of advancing these innovative immune-modulatory antibodies for patients who urgently need better treatment options."- Martin Welschof, CEO of BioInvent.
EVENTS IN THE FIRST QUARTER
(R) Promising data in ongoing Phase 2a study for BI-1808 with KEYTRUDA (pembrolizumab) for the treatment of recurrent ovarian cancer
Updated clinical data sets solidify potential for both BI-1808 and pembrolizumab combination in ovarian cancer and BI-1206 triplet for the treatment of NHL, see pages 6 and 7 in the year-end report
Nomination of two new board members ahead of 2026 Annual General Meeting; Kate Hermans and Scott Zinober
Phase 3 milestone achieved for HMI-115 in endometriosis
EVENTS AFTER THE END OF THE PERIOD
BI-1808 plus KEYTRUDA data in recurrent ovarian cancer to be presented at the 2026 ASCO Annual Meeting
(R)= Regulatory event
FINANCIAL INFORMATION
First quarter 2026
• Net sales SEK 13.4 (22.1) million.
• Profit/loss after tax SEK -119.2 (-116.6) million.
• Profit/loss after tax per share before and after dilution SEK -1.81 (-1.77).
• Cash flow from operating activities SEK -132.8 (-120.0) million.
• Liquid funds, current and long-term investments as of March 31, 2026: SEK 456.5 (742.2) million.
The complete interim report is available for download below and on the company's website under Financial reports.
About BioInvent
BioInvent International AB (Nasdaq Stockholm: BINV) is a clinical-stage biotech company that discovers and develops novel and first-in-class immuno-modulatory antibodies for cancer therapy, with drug candidates in ongoing clinical programs in Phase 1/2 trials for the treatment of hematological cancer and solid tumors. The Company's validated, proprietary F.I.R.S.T technology platform identifies both targets and the antibodies that bind to them, generating many promising new immune-modulatory candidates to fuel the Company's own clinical development pipeline and providing licensing and partnering opportunities.
The Company generates revenues from research collaborations and license agreements with multiple top-tier pharmaceutical companies, as well as from producing antibodies for third parties in the Company's fully integrated manufacturing unit. More information is available at www.bioinvent.com.
For further information, please contact:
Cecilia Hofvander, VP Investor Relations
Phone: +46 (0)46 286 85 50
Email: cecilia.hofvander@bioinvent.com
BioInvent International AB (publ)
Co. Reg. No.: 556537-7263
Visiting address: Ideongatan 1
Mailing address: 223 70 LUND
Phone: +46 (0)46 286 85 50
www.bioinvent.com
Attachments
BioInvent 2026 Q1 EN
SOURCE: BioInvent International
View the original press release on ACCESS Newswire:
https://www.accessnewswire.com/newsroom/en/biotechnology/bioinvent-international-ab-interim-report-january-march-2026-1162324
